Centralised Molecular Diagnostics, Apollo Hospitals, Chennai, India.
Department of Haematology, Apollo Hospitals, Chennai, India.
Cancer Rep (Hoboken). 2020 Dec;3(6):e1288. doi: 10.1002/cnr2.1288. Epub 2020 Sep 3.
Driver mutations are seen in 80% of lung adenocarcinomas, and they influence prognosis and choice of therapy.
Aim of this study was to analyse the frequency of epidermal growth factor receptor (EGFR) mutations, ALK and ROS1 rearrangements and their association with age and gender in non-small cell lung cancer reported from a tertiary care center in South India.
Tumors from patients with non-small cell carcinoma of lung were evaluated for EGFR mutations, ALK and ROS1 rearrangements and their association with age and gender were studied.
Two thirds of non-small cell carcinomas had driver mutations or rearrangements. EGFR mutation was common and seen in 34.1%, whereas ALK rearrangement was seen in 11.1% and ROS1 rearrangement in 2% patients. Among EGFR mutations, most common were Exon 19 deletion and L858R seen in 21.3% and 11% of patients, respectively. Adenocarcinoma was the histologic diagnosis in 81% to 85% of patients with exon 19 deletion and L858R mutation, respectively. EGFR mutation frequency in patients less than 36 years was 13.6%, whereas in older patients, it varied from 34% to 36%. Exon 19 deletion was seen in 29.8% females and 17.2% of males.
EGFR mutations are more common than ALK and ROS1 rearrangements. They are more common in females. Patients less than 36 years have reduced frequency of EGFR mutations. Exon 19 deletion and L858R are most common and are more prevalent in lung adenocarcinomas. Rare EGFR mutations are seen in patients aged more than 50 years.
在 80%的肺腺癌中可见驱动基因突变，它们影响预后和治疗选择。
本研究旨在分析在印度南部一家三级护理中心报告的非小细胞肺癌中表皮生长因子受体（EGFR）突变、ALK 和 ROS1 重排的频率及其与年龄和性别之间的关系。
评估非小细胞肺癌患者的肿瘤是否存在 EGFR 突变、ALK 和 ROS1 重排，并研究其与年龄和性别之间的关系。
三分之二的非小细胞癌存在驱动基因突变或重排。EGFR 突变很常见，占 34.1%，而 ALK 重排占 11.1%，ROS1 重排占 2%。在 EGFR 突变中，最常见的是外显子 19 缺失和 L858R，分别占患者的 21.3%和 11%。腺癌是 19 外显子缺失和 L858R 突变患者的组织学诊断，分别占 81%至 85%。年龄小于 36 岁的患者 EGFR 突变频率为 13.6%，而年龄较大的患者则为 34%至 36%。外显子 19 缺失在女性中的发生率为 29.8%，在男性中为 17.2%。
EGFR 突变比 ALK 和 ROS1 重排更为常见。它们在女性中更为常见。年龄小于 36 岁的患者 EGFR 突变频率较低。外显子 19 缺失和 L858R 是最常见的，在肺腺癌中更为常见。年龄大于 50 岁的患者罕见 EGFR 突变。
